PROSTATE CANCER PREVENTION TRIAL (PCPT) PUBLICATIONS

1993-June 30, 2010

MANUSCRIPTS

1993 S9217 Chemoprevention of prostate cancer with finasteride. I Thompson, P Feigl, C

Coltman. Cancer Prevention Dec:1-15, 1993.

1994 S9217 Prostate cancer prevention: Risk reduction through life-style, diet, and

chemoprevention. KE Greco, L Kulawiak. Oncology Nursing Forum 21(9):1504-1511, 1994. PMID: 7816677

S9217 The prostate cancer prevention trial. A low-risk, high-accrual study. J O'Connor.

Oncology Issues 9(5):20-24, 1994. S9217 Chemoprevention of prostate cancer. IM Thompson, CA Coltman, OW Brawley,

A Ryan. Seminars in Urology 13(2):122-129, 1995. PMID: 7638469

1995 S9217 Chemoprevention of prostate cancer with finasteride. I Thompson, P Feigl, C

Coltman. Important Advances in Oncology VT DeVita, S Hellman, SA Rosenberg, eds, J.B. Lippincott Company pp. 57-76, 1995. PMID: 7672814

S9217 Design of the prostate cancer prevention trial (PCPT). P Feigl, B Blumenstein, I

Thompson, J Crowley, M Wolf, BS Kramer, CA Coltman Jr, OW Brawley, LG Ford. Controlled Clinical Trials 16:150-163, 1995. PMID: 7540965

1996

S9217 Chemoprevention of prostate cancer with finasteride. I Thompson, P Feigl, C Coltman. Principles & Practice of Oncology 10(3):1-18, 1996.

*S9217 Screening for prostate cancer: Opportunities for prevention. IM Thompson, CA

Coltman. Seminars in Urologic Oncology 14(2) (Suppl 2):4-11, 1996. PMID: 8725886

1997

S9217 Chemoprevention of prostate cancer: The prostate cancer prevention trial. IM Thompson, CA Coltman Jr, J Crowley. The Prostate 33:217-221, 1997. PMID: 9365551

1998

S9217 Army and Air Force leadership in the prostate cancer prevention trial. J Allerton, T Seay, S Optenberg, CA Coltman Jr, B Higgins, I Thompson. Urology 51(Suppl 4A):64-66, 1998.

PMID: 9586599

1999 S9217 Prostate cancer prevention trial (PCPT) update. CA Coltman Jr, IM Thompson Jr,

P Feigl. European Urology 35:544-547, 1999. PMID: 10325520 S9217 Letters to the Editor: The effect of finasteride on the prostate gland in men with

elevated serum prostate-specific antigen level. CA Coltman. British Journal of Cancer 81(1):184-185, 1999. PMID: 10487632

S9217 Validity of short food frequency questionnaires used in cancer chemoprevention

trials: results from the prostate cancer prevention trial. ML Neuhouser, AR Kristal, D McLerran, RE Patterson, J Atkinson. Cancer Epidemiology, Biomarkers & Prevention 8:721-725, 1999. PMID: 10744133

2000

S9217 Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. CM Moinpour, LC Lovato, IM Thompson Jr, JE Ware Jr, PA Ganz, DL Patrick, SA Shumaker, GW Donaldson, A Ryan, CA Coltman Jr. Journal of Clinical Oncology 18(9):1942-1953, 2000.

PMID: 10784636 S9217 Television and news print media are effective in recruiting potential participants in

a prostate cancer chemoprevention trial. TDK Chung, II Park, L Ignacio, R Catchatourian, M Kopnick, E Davison, G Conrad, AM Awan, D Crawford, S. Vijayakumar. International Journal of Cancer 90:302-304, 2000. PMID: 11091355

S9217 Minority recruitment in the prostate cancer prevention trial. CM Moinpour, JO

Atkinson, SM Thomas, S Millon Underwood, C Harvey, J Parzuchowski, LC Lovato, AM Ryan, MS Hill, E DeAntoni, ER Gritz, IM Thompson Jr, CA Coltman Jr. Annals of Epidemiology 10(S8):S85-S91, 2000. PMID: 11189097

S9217 Letters to the editor: RE: RE: Chemoprevention of Urological Cancer. IM

Thompson, CA Coltman. Journal of Urology 164(4):1321-1322, 2000. PMID: 10992404

2001

S9217 The prostate cancer prevention trial: current status and lessons learned. IM Thompson Jr, J Kouril, EA Klein, CA Coltman, A Ryan, P Goodman. Urology 57(Suppl 4A):230-234, 2001. PMID: 11295634

S9217 Dietary supplement use in the prostate cancer prevention trial: implications for

prevention trials. ML Neuhouser, AR Kristal, RE Patterson, PJ Goodman, IM Thompson. Nutrition and Cancer 39(1):12-18, 2001. PMID: 11588893

2002

S9217 Energy from fat is associated with obesity in US men: results from the Prostate Cancer Prevention Trial. J Satia-Abouta, RE Patterson, RN Schiller, AR Kristal. Preventive Medicine 34:493-501, 2002. PMID: 11969348

S9217 Biomarker-based methods for determining noncompliance in a prevention trial.

DK Pauler, KB Gower, PJ Goodman, JJ Crowley, IM Thompson. Controlled Clinical Trials 23:675-685, 2002. PMID: 12505245

2003

S9217 The influence of finasteride on the development of prostate cancer. IM Thompson, PJ Goodman, CM Tangen, MS Lucia, GJ Miller, LG Ford, MM Lieber, RD Cespedes, JN Atkins, SM Lippman, SM Carlin, A Ryan, CM Szczepanek, JJ Crowley, CA Coltman Jr. New England Journal of Medicine 349:215-224, 2003. PMID: 12824459

S9217 The prostate cancer prevention trial: design, status, and promise. IM Thompson

C Tangen, P Goodman. World Journal of Urology 21:28-30, 2003. PMID: 12756491

S9217 Prevention of prostate cancer with finasteride: US/European perspective. IM Thompson, EA Klein, SM Lippman, CA Coltman, B Djavan. European Urology 44(6):650-655, 2003.

PMID: 14644115 S9217 Challenges and opportunities to the design and implementation of

chemoprevention trials for prostate cancer. IM Thompson, JA Basler, R Leach, D Troyer, E Klein, O Brawley.

Urologic Oncology 21(1):73-78, 2003. PMID: 12684131 S9217/0000 Prostate cancer prevention: what do we know now and when will we know more?

IM Thompson, J Basler, D Hensley, D vonMerveldt, CA Jenkins, B Higgins, R Leach, D Troyer, B Pollock. Clinical Prostate Cancer 1(4):215-220, 2003. PMID: 15040879

S9217 Estimating the impact of new clinical trial proven cancer therapy and cancer

chemo-prevention on population mortality: the Karnofsky memorial lecture. JM Unger, M LeBlanc, JJ Crowley, HB Grossman, RB Natale, AJ Wozniak, JR Berenson, AF List, WA Peters, RC Flanigan, JS Macdonald, M Al-Saffaf,IM Thompson, CA Coltman, Jr. Journal of Clinical Oncology 21(23 Suppl):2465s-252s, 2003. PMID: 14645404

2004

S9217 Prevalence of prostate cancer among men with a prostate-specific antigen level of <4.0 ng per milliliter. IM Thompson, DK Pauler, PJ Goodman, CM Tangen, MS Lucia, HL Parnes, LM Minasian, LG Ford, SM Lippman, ED Crawford, JJ Crowley, CA Coltman Jr. New England Journal of Medicine 350(22):2239-2246, 2004. PMID: 15163773

S9217 Implementation of the prostate cancer prevention trial (PCPT). PJ Goodman, CM

Tangen, JJ Crowley, SM Carlin, A Ryan, CA Coltman Jr, LG Ford, IM Thompson. Controlled Clinical Trials 25:203-222, 2004. PMID: 15020037

S9217 The person-years saved model and other methodologies for assessing the

population impact of cancer-prevention strategies. JM Unger, M LeBlanc, IM Thompson, CA Coltman, Jr. Urologic Oncology: Seminars and Original Investigations 22:362-368, 2004.

PMID: 15282898 S9217 The Prostate Cancer Prevention Trial: current status. B Higgins, IM Thompson.

Journal of Urology 171(2 pt 2):S15-17; discussion S8, 2004. S9217/S0000 Prostate cancer chemoprevention: an overview of United States trials. A

Barqawi, IM Thompson, ED Crawford. Journal of Urology 171:S5-S9, 2004. PMID: 14713745

S9217/S0000 Statistical design issues and other practical considerations for conducting phase

III prostate cancer prevention trials. CM Tangen, PJ Goodman, JJ Crowley, IM Thompson. Journal of Urology 171(2 pt 2):S64-7, 2004. PMID: 14713757

S9217 Prostate-specific antigen: a review of the validation of the most commonly used

cancer biomarker. J Hernandez, IM Thompson. Cancer 101(5):894-904, 2004. PMID: 15329895

2005

S9217 Estimated impact of the prostate cancer prevention trial on population mortality. JM Unger, IM Thompson Jr, M LeBlanc, JJ Crowley, PJ Goodman, LG Ford, CA Coltman Jr. Cancer 103(7):1375-1380, 2005. PMID: 15739207

S9217 Comment on: Estimated impact of the prostate cancer prevention trial on population mortality. SB Zeliadt, R Etzioni, AR Kristal. Cancer 104(7):1556-1557, 2005. PMID: 16015625

S9217 Operating characteristics of prostate-specific antigen in men with an initial PSA

level of 3.0 ng/mL or lower. IM Thompson, DP Ankerst, C Chi, MS Lucia, PJ Goodman, JJ Crowley, HL Parnes, CA Coltman. The Journal of the American Medical Association 294(1):66-70, 2005. PMID: 15998892

S9217 Assessing benefit and risk in the prevention of prostate cancer: the prostate

cancer prevention trial revisited. EA Klein, CM Tangen, PJ Goodman, SM Lippman, IM Thompson. Journal of Clinical Oncology 23(30):7460-7466, 2005. PMID: 16622122

S9217 Erectile dysfunction and subsequent cardiovascular disease. IM Thompson, CM

Tangen, PJ Goodman, JL Probstfield, CM Moinpour, CA Coltman. JAMA 294(23):2996-3002, 2005. PMID: 16414947

S9217 Long-term effects of finasteride on prostate specific antigen levels: results from

the prostate cancer prevention trial. RD Etzioni, N Howlader, PA Shaw, DP Ankerst, DF Penson, PJ Goodman, IM Thompson. Journal of Urology 174:877-881, 2005. PMID: 16093979

S9217 Phase III prostate cancer prevention trials: are the costs justified? IM Thompson,

CM Tangen, EA Klein, SM Lippman. Journal of Clinical Oncology 23(32):8161-8164, 2005. PMID: 16278467

S9217 Mechanisms of disease: prostate cancer – a model for cancer chemoprevention

in clinical practice. ED Canby-Hagino, IM Thompson. Nature Clinical Practice Oncology, 2(5):255-261, 2005. PMID: 16264961

S9217 Lifetime implications and cost-effectiveness of using finasteride to prevent

prostate cancer. SB Zeliadt, RD Etzioni, DF Penson, IM Thompson, SD Ramsey. American Journal of Medicine 118(8):850-857, 2005. PMID: 16084177

.

2006 S9217 The evolution of the PCPT from clinical to molecular analyses. A Hoque. Nature

Clinical Practice Oncology 3(11):581, 2006. PMID: 17080169 S9217 External validation of the Prostate Cancer Prevention Trial risk calculator in a

screened population. DJ Parekh, DP Ankerst, BA Higgins, J Hernandez, E Canby-Hagino, T Brand, DA Troyer, RJ Leach, IM Thompson. Urology 68(6):1152-1155, 2006. PMID: 1716936

S9217 Assessing prostate cancer risk: results from the prostate cancer prevention trial.

IM Thompson, DP Ankerst, C Chi, PJ Goodman, CM Tangen, MS Lucia, Z Feng, HL Parnes, CA Coltman Jr. Journal of the National Cancer Institute 98(8):529-534, 2006. PMID: 16622122

S9217 The prostate cancer prevention trial: design, biases, and interpretation of study

results. PJ Goodman, IM Thompson Jr, CM Tangen, JJ Crowley, LG Ford, CA Coltman Jr. Journal of Urology 175:2234-2242, 2006. PMID: 16697846

S9217 Associations of demographic and lifestyle characteristics with prostate-specific

antigen (PSA) concentration and rate of PSA increase. AR Kristal, C Chi, CM Tangen, PJ Goodman, R Etzioni, IM Thompson. Cancer 106(2):320-328, 2006. PMID: 16342294

S9217 Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer

prevention trial. Z Gong, ML Neuhouser, PJ Goodman, D Albanes, C Chi, AW Hsing, SM Lippman, EA Platz, MN Pollak, IM Thompson, AR Kristal. Cancer Epidemiol Biomarkers Prev 15(10):1977-1983, 2006. PMID: 17035408

S9217 Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. IM

Thompson, C Chi, DP Ankerst, PJ Goodman, CM Tangen, SM Lippman, MS Lucia, HL Parnes, CA Coltman, Jr. Journal of the National Cancer Institute 98(16):1128-1133, 2006. PMID: 16912265

S9217 New answers from the Prostate Cancer Prevention Trial on the chemoprevention

of prostate cancer. DP Ankerst, IM Thompson. Archivio Italiano di Urologia, Andrologia 78(4):154-156, 2006. PMID: 17269622

S9217 Merging digital rectal exam, family history, age and prostate-specific antigen to

create a decision-making tool. DP Ankerst, IM Thompson. Archivio Italiano di Urologia, Andrologia 78(4):143-146, 2006. PMID: 17269618

S9217 Sensitivity and specificity of prostate-specific antigen for prostate cancer detection

with high rates of biopsy verification. DP Ankerst, IM Thompson. Achivio Italiano di Urologia, Andrologia 78(4):125-129, 2006. PMID: 17269614

S9217 Chemoprevention of prostate cancer with finasteride. ED Canby-Hagino, TC

Brand, J Hernandez, IM Thompson. Expert Opinion on Pharmacotherapy 7(7):899-905, 2006. PMID: 16634712

S9217 Role of 5 alpha-reductase inhibitors in the management of prostate cancer. SJ

Hudak, J Hernandez, IM Thompson. Clinical Interventions in Aging 1(4):425-431, 2006. PMID: 18046919

S9217 Modeling the effect of a preventive intervention on the natural history of cancer:

application to the prostate cancer prevention trial. P Pinsky, R Etzioni, N Howlader, P Goodman, IM Thompson. International Journal of Biostatistics 2(1): article 12, 2006. Available at: http://www.bepress.com/ijb/vol2/iss1/12.

2007

S9217 Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. IM Thompson, CM Tangen, PJ Goodman, MS Lucia, HL Parnes, SM Lippman, CA Coltman, Jr. Journal of Urology 177:1749-1752, 2007. PMID: 17437804

S9217 Longitudinal analysis of sexual function reported by men in the prostate cancer

prevention trial. CM Moinpour, AK Darke, GW Donaldson, IM Thompson, Jr, C Langley, DP Ankerst, DL Patrick, JE Ware, Jr, PA Ganz, SA Shumaker, SM Lippman, CA Coltman, Jr. Journal of the National Cancer Institute 99:1025-1035, 2007. PMID: 17596576

S9217 Is prostate-specific antigen velocity useful in early detection of prostate cancer: A

critical appraisal of the evidence. RD Etzioni, DP Ankerst, NS Weiss, LY Inoue, IM Thompson. Journal of the National Cancer Institute 99(20):1510-1515, 2007. PMID: 17925534

S9217 Race/ethnicity, obesity, health related behaviors and the risk of symptomatic

benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. AR Kristal, KB Arnold, JM Schenk, ML Neuhouser, N Weiss, P Goodman, CM Antvelink, DF Penson, IM Thompson. Journal of Urology 177:1395-1400, 2007. PMID: 17382740

S9217 Finasteride decreases the risk of prostatic intraepithelial neoplasia. IM

Thompson, SM Lucia, MW Redman, A Darke, FG La Rosa, HL Parnes, SM Lippman, CA Coltman. Journal of Urology 178:107-110, 2007. PMID: 17499284

S9217 Prediction of prostate cancer for patients receiving finasteride: results from the

Prostate Cancer Prevention Trial. IM Thompson, DP Ankerst, C Chi, PJ Goodman, CM Tangen, SM Lippman, MS Lucia, HL Parnes, CA Coltman, Jr. Journal of Clinical Oncology 25(21): 3076-3081, 2007. PMID: 17634486

S9217 Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention

Trial. MS Lucia, JI Epstein, PJ Goodman, AK Darke, VE Reuter, F Civantos, CM Tangen, HL Parnes, SM Lippman, F La Rosa, MW Kattan, ED Crawford, LG Ford, CA Coltman Jr, IM Thompson. Journal of the National Cancer Institute 99(18):1375-1383, 2007. PMID: 17848673

S9217 Looking back at PCPT: looking forward to new paradigms in prostate cancer

screening and prevention. E Canby-Hagino, J Hernandez, TC Brand, I Thompson. European Urology 51(1):27-33, 2007. PMID: 17030406

S9217 Prostate-specific antigen in the early detection of prostate cancer. IM Thompson,

DP Ankerst. Canadian Medical Association Journal 176(13):1853-1858, 2007. PMID: 17576986

2008 S9217 Finasteride, prostate cancer, and weight gain: evidence for genetic or

environmental factors that affect cancer outcomes during finasteride treatment. Y Song, C Tangen, P Goodman, HL Parnes, MS Lucia, IM Thompson, AR Kristal. The Prostate 68:281-286, 2008. PMID: 18163420

S9217 Extraction of DNA from serum for high-throughput geno-typing: findings from pilot

studies within the Prostate Cancer Prevention Trial. A Hoque, P. Goodman, CB Ambrosone, WD Figg, DK Price, W Kopp, X Wu, J Conroy, TA Lehman, RM Santella. Urology 71(5):967-970, 2008. PMID: 18267333.

S9217 Finasteride does not increase the risk of high-grade prostate cancer: a bias-

adjusted modeling approach. MW Redman, CM Tangen, PJ Goodman, MS Lucia, CA Coltman, IM Thompson. Cancer Prevention Research 1(3):174-81, 2008. PMID: 19138953

S9217 Pathologic characteristics of cancers detected in the Prostate Cancer Prevention

Trial: implications for prostate cancer detection and chemoprevention. MS Lucia, A Darke, PJ Goodman, FG LaRosa, HL Parnes, LG Ford, CA Coltman, Jr., IM Thompson. Cancer Prevention Research 1(3):167-173, 2008. PMID: 19138952

S9217 Does the level of prostate cancer risk affect cancer prevention with finasteride?

IM Thompson, CM Tangen, HL Parnes, SM Lippman, CA Coltman, Jr. Urology, 71(5):854-857, 2008. PMID: 18455628

S9217 Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. AR Kristal, JM Schenk, Y Song, KB arnold, ML Neuhouser, PJ Goodman, DW Lin, FZ Stanczyk, IM Thompson. American Journal of Epidemiology 168(12):1416-24, 2008. PMID: 18945688

S9217 Prostate cancer chemoprevention: update of the prostate cancer prevention trial

findings and implications for clinical practice. JA Sarvis, IM Thompson. Current Oncology Reports, 10(6):529-532, 2008. PMID: 18928669

S9217 Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of

benign prostate hyperplasia in the prostate cancer prevention trial. ML Neuhouser, J Schenk, YJ Song, CM Tangen, PJ Goodman, M Plaak, DF Penson, IM Thompson, AR Kristal. Prostate 68(13):1477-1486, 2008. PMID: 18618736

S9217 The performance of prostate specific antigen for predicting prostate cancer is

maintained after a prior negative prostate biopsy. IM Thompson, CM Tangen, DP Ankerst, C Chi, MS Lucia, P Goodman, H Parnes, CA Coltman, Jr. Journal of Urology 180(2):544-547, 2008.

PMID: 18550097 S9217 Integrating the predictiveness of a marker with its performance as a classifier. MS

Pepe, Z Feng, Y Huang, G Longton, R Prentice, IM Thompson, Y Zheng. American Journal of Epidemiology 167(3):362-368, 2008. PMID: 17982157

S9217 The Prostate Cancer Prevention Trial and the future of chemoprevention. IM

Thompson, CM Tangen, MS Lucia. British Journal of Urology International 101(8):933-934, 2008. PMID: 18353157

S9217 Dietary patterns, supplement use, and the risk of symptomatic benign prostatic

hyperplasia: results from the prostate cancer prevention trial. AR Kristal, KB Arnold, JM Schenk, ML Neuhouser, P Goodman, DF Penson, IM Thompson. American Journal of Epidemiology 167(8):925-934, 2008. PMID: 18263602

S9217 Consumption of dietary supplements and over-the-counter and prescription

medications in men participating in the Prostate Cancer Prevention Trial at an academic center. EM Grainger, HS Kim, JP Monk, SA Lemeshow, M Gong, RR Bahnson, SK Clinton. Urologic Oncology 26(2):125-132, 2008. PMID: 18312929

S9217 Does finasteride affect the severity of prostate cancer? A causal sensitivity

analysis. BE Shepherd, M Redman, DP Ankerst. Journal of the American Statistical Association 103:484):1392-1404, 2008 (PMED not applicable)

S9217 Predicting prostate cancer risk through incorporation of prostate cancer gene

3.Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I. Journal of Urology. 180(4):1303-1308, 2008. PMID: 18707724

2009

S9217 Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. S Sutcliffe, JF Alderete, C Till, PJ Goodman, AW Hsing, JM Zenilman, AM DeMarzo, EA Platz. International Journal of Cancer 124(9):2082-2087, 2009. PMID: 19117055.

S9217 Serum adiponectin, c-peptide and leptin and risk of symptomatic benign prostatic

hyperplasia: results from the Prostate Cancer Prevention Trial. JM Schenk, Kristal AR, ML Neuhouser, CM Tangen, E White, DW Lin, IM Thompson. Prostate 69(12):1303-1311, 2009. PMID: 19475640

S9217 Alcohol consumption, finasteride, and prostate cancer risk: results from the

Prostate Cancer Prevention Trial. Z Gong, AR Kristal, JM Schenk, CM Tangen, PJ Goodman, IM Thompson. Cancer 115(16):3661-3669, 2009 PMID:19598210

S9217 The performance characteristics of prostate-specific antigen for prostate cancer

screening. IM Thompson, Jr, DP Ankerst. In Prostate Cancer Screening, 2nd edition, D Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, NY, chapter 6, pp. 61-70, 2009.

S9217 The performance of PSA for predicting prostate cancer after a prior negative

prostate biopsy. C Tangen. In Prostate Cancer Screening, 2nd edition, D Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, NY, chapter 7, pp. 71-78, 2009.

S9217 Development of the Prostate Cancer Prevention Trial prostate cancer risk

calculator. DP Ankerst, IM Thompson. In Prostate Cancer Screening, 2nd edition, D Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, NY, chapter 12, pp. 195-203, 2009.

S9217 Prostate-specific antigen and its role on the Prostate Cancer Prevention Trial. CM

Tangen, PJ Goodman. In Prostate Cancer Screening, 2nd edition, D Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, NY, chapter 24, pp. 333-348, 2009.

S9217 Men with low serum cholesterol have a lower risk of high-grade prostate cancer in

the placebo arm of the Prostate Cancer Prevention Trial (Southwest Oncology Group Study S9217). EA Platz, C Till, PJ Goodman, HL Parnes, WD Figg, D Albanes, ML Neuhouser, AR Kristal, EA Klein, IM Thompson. Cancer Epidemiology, Biomarkers and Prevention, 18(11):2807-2813, 2009. PMID: 19887582

S9217 Chemoprevention of prostate cancer. IM Thompson, CM Tangen, PJ Goodman,

MS Lucia, EA Klein. Journal of Urology 182(2):499-507, 2009. PMID: 19524966

2010 S9217 Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in

genotyping and haplotyping studies. L Musumeci, JW Arthur, F Cheung, A Hoque, S Lippman, J Richardt. Human Mutation 31(1):67-73, 2010. PMID: 19877174

S9217 Human papillomavirus types 16, 18 and 31 serostatus and prostate cancer risk in

the Prostate Cancer Prevention Trial. S Sutcliffe, RP Viscidi, C Till, P Goodman, AM Hoque, AW Hsing, IM Thompson, JM Zenilman, AM DeMarzo, EA Platz. Cancer Epidemiology Biomarkers and Prevention 19(2):614-618, 2010. PMID: 20142255

S9217 Transparency and reproducibility in data analysis: The Prostate Cancer

Prevention Trial. SG Baker, AK Darke, P Pinsky, HL Parnes, BS Kramer. Biostatistics 11(3):413-418, 2010 PMID: 20173101

S9217 Finasteride modifies the relation between serum c-peptide and prostate cancer risk: results from the prostate cancer prevention trial. ML Neuhouser, C Till, A Kristal, P Goodman, A Hoque, EA Platz, AW Hsing, D Albanes, HL Parnes, M Pollak. Cancer Prevention Research 3(3):279-289, 2010 PMID: 20179296

S9217 Biomarkers of systemic inflammation and risk of incident, symptomatic benign

prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. JM Schenk, AR Kristal, ML Neuhouser, CM Tangen, E White, DW Lin, M Kratz, IM Thompson. American Journal of Epidemiology 171(5):571-582, 2010.

PMID: 2014396 S9217 Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the prostate cancer

prevention trial. AR Kristal, DK Price, C Till, JM Schenk, ML Neuhouser, S Ockers, DW Lin, IM Prostate 70(6):584-90, 2010. PMID: 19938041

S9217 Intra-individual variation in serum C-reactive protein over 4 years: an implication

for epidemiologic studies. E Platz, S Sutclilffe, AM DeMarzo, CG Drake, N Rifai, A Hsing, A Hoque, M. Neuhouser, P Goodman, A Kristal. Cancer Causes and

Control 21(6):847-851, 2010. PMID: 20135215 S9217 Transition of a clinical trial into translational research: the Prostate Cancer

Prevention Trial experience. P Goodman, CM Tangen, A Kristal, IM Thompson, MS Lucia, EA Platz, WD Figg, A Hoque, H Hsing, M Neuhouser, H Parnes, J Richardt, R Santella, C Till. Cancer Prevention Research, accepted 6/29/10.

ABSTRACTS

1994 S9217 Chemoprevention of prostate cancer with finasteride, an Intergroup trial. CA

Coltman Jr, J Unger, IM Thompson. Annals of Oncology 5 (Suppl 8):65 (#P324), 1994.

1995

S9217 Chemoprevention of prostate cancer with finasteride: An Intergroup trial. CA Coltman Jr, J Unger, I Thompson. Cancer Investigation 13 (Suppl 1):43 (#36), 1995.

1996

*S9217 Prostate cancer prevention trial. BH Zoltick. Presented at the AUAA** Annual Assembly, Orlando, Florida, May 3-7, 1996.

*S9217 The prostate cancer prevention trial: Efforts to increase the recruitment of

minority participants. CM Moinpour. Poster presentation at the Conference on the Recruitment and Retention of Minority Participants in Clinical Cancer Research, Washington, DC, 1/26-27/1996.

*S9217 The prostate cancer prevention trial. A Ryan. Prevention/Early Detection SIG

Newsletter 6(3), 1996. 1997

*S9217 Utility of the enrollment period in the Prostate Cancer Prevention Trial (PCPT). PJ Goodman, L Lovato, A Ryan, J Crowley, C Moinpour, I Thompson. Controlled Clinical Trials 18(3S)(#19):52S, June 1997.

*S9217 Data operations management with clinical datafax: The prostate cancer prevention trial (PCPT) experience. AM Ryan, L Emel, P Goodman. Controlled Clinical Trials 18(3S)(#P74):156S, June 1997.

2000

*S9217 Dietary supplement use in the prostate cancer prevention trial: implications for study findings. ML Neuhouser, AR Kristal, RE Patterson, IM Thompson. American Society of Prevention Oncology #76, 2000.

2001

S9217 Promoting adherence to the prostate cancer prevention trial end of study biopsy requirement. AM Ryan, P Goodman, S Hill, C Moinpour. Controlled Clinical Trials 22(2S):88S (#P71), 2001.

2002

S9217 Biomarker-based methods for determining non-compliance in a prevention trial. KB Gower, DK Pauler, PJ Goodman. Controlled Clinical Trials 23(2S):49S-50S (#26), 2002.

2003

S9217 The prostate cancer prevention trial: Did the adherence interventions for the end of study biopsy really work? S Carlin, P Goodman, C Moinpour, S Hill. Controlled Clinical Trials 24(3S):P22, 2003.

2004

S9217 The prostate cancer prevention trial: the association of study site and participant adherence interventions to the study site end-of-study biopsy rates. S Carlin, P Goodman, C Moinpour, C Tangen. Clinical Trials 1 (Suppl 1):P45, 2004.

2005

*S9217 Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT). MS Lucia, A Darke, P Goodman, C Tangen, CA Coltman, IM Thompson. Journal of Urology 173(4):451 (#1664), 2005.

*S9217 Prostate specific antigen (PSA) as a predictor of adverse pathological features at

prostatectomy in the Prostate Cancer Prevention Trial (PCPT). MS Lucia, P Goodman, C Tangen, CA Coltman, IM Thompson. Journal of Urology 173(4):143 (#525), 2005.

*S9217 The performance characteristics of prostate-specific antigen. IM Thompson Jr,

DP Ankerst, C Chi, P Goodman, C Tangen, CA Coltman Jr. Journal of Urology 173(4):143 (#526), 2005.

S9217 Assessing benefit and risk in the prevention of prostate cancer: the Prostate

Cancer Prevention Trial revisited. E Klein, C Tangen, P Goodman, S Lippman, I Thompson. 2005 ASCO Prostate Cancer Symposium, abstract no. 4, 2005.

S9217 Individual prediction of prostate cancer based on prostate specific antigen. C Chi,

D Pauler Ankerst, P Goodman. Clinical Trials 2 (Suppl 1):P40, 2005.

2006 S9217 Association of erectile dysfunction and subsequent cardiovascular disease. IM

Thompson Jr, J Probstfield, C Tangen, P Goodman, C Moinpour, CA Coltman Jr. Proc of the AUA, Journal of Urology 175(4) Suppl:429 (#1333), 2006.

S9217 Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the Prostate Cancer Prevention Trial. IM Thompson, C Chi, P Goodman, C Tangen, D Pauler Ankerst, MS Lucia, CA Coltman, Jr. Proc of the AUA, Journal of Urology 175(4) Suppl:152, (#470), 2006.

2009

S9217/S0000 Cancer prevention clinical trials: assessing for disparities in recruitment in Hawaii. E Bantum, I Cheng, K Cassel, L Ka’opua, J Berenberg. American Association of Cancer Research, Proceedings of Frontiers in Cancer Prevention Research, abstract #B26, p. 116, 2009.

*Presented